Here are the pertinent facts about Jakafi for uncontrolled PV
Only IDIOTS who misinterpreted today's today's press releaserelease would give away their shares for $45 in AH.
"RELIEF was designed to provide us with additional information regarding symptom improvement and is not required for FDA approval. The patients recruited into the RELIEF study had less advanced PV compared to those in RESPONSE, our larger pivotal Phase III study which formed the basis of the sNDA, and which met the primary endpoint of improved hematocrit control and reduced spleen size in patients with uncontrolled PV,” stated Richard Levy, M.D., Executive Vice President, Chief Drug Development & Medical Officer of Incyte.
16,700 shares treaded at around $46 a share - $770,000 in value was sold and $670 mill in market cap shaved, over a trial that has no bearing on the drug's approval. Amazing. The control arm had a six fold better than normal efficacy, which is why ICY's drug didn't reach statistical significance. I think once they dig into the data, they'll figure out why. In the meantime, it doesn't matter!